Precision medicine biotechnology

From biological complexity to clinically meaningful discovery.

Bioada advances diagnostics and therapeutics by identifying causal disease biology, extracting reproducible signals and designing for translation from the start.

Explore the portfolio ↘
Abstract interconnected biological network
01

Diagnostics

02

Therapeutics

03

Multi-omics discovery

The biological thesis

Disease is not driven by isolated molecular events.

It emerges from coordinated and executable biological programs. Bioada looks beyond statistical association to identify the mechanisms, states and signals that can support real clinical decisions.

01

Causal disease biology

Distinguishing disease-driving programs from downstream molecular consequence.

02

Reproducible signal extraction

Prioritizing compact, robust biomarker signatures with cross-cohort relevance.

03

Translational intelligence

Connecting mechanistic insight to patient selection, clinical feasibility and development strategy.

Discovery portfolio

Biology with a path to application.

Bioada’s portfolio spans blood-based diagnostics and therapeutically actionable disease biology across oncology, neurodegeneration and rare disease.

Diagnostic programs

Blood-based · Minimal-gene · Scalable

Breast cancer

Single-gene blood biomarker with strong diagnostic performance and scalability potential.

Pancreatic cancer

Two-gene blood signature integrated with driver discovery and translational targeting opportunities.

Neurological disease

Minimal-gene blood-based programs in Alzheimer’s and Parkinson’s disease.

FSHD

A blood-based biomarker program designed around reproducibility and accessible deployment.

Multi-cancer detection

A compact microRNA panel developed to identify signals across multiple cancer types.

Therapeutic discovery

Driver biology · Mechanism · Intervention

Parkinson’s disease

Glioblastoma

Pancreatic cancer

Breast cancer

Multiple sclerosis

Lung cancer

FSHD

Molecular structures in a cellular environment

Programs are built around novel driver biology, translationally actionable mechanisms and patient-specific therapeutic opportunities—including target discovery and drug-repurposing hypotheses.

Scientist analyzing biological data

Designed for translation

Discovery is only valuable when it can move.

Bioada integrates biological robustness with the realities of development: patient selection, clinical feasibility, delivery, exposure, formulation and deployability.

  • Mechanistic rationale
  • Patient stratification
  • Biomarker strategy
  • Therapeutic positioning

Partner with Bioada

Advance the right biology.

We engage through co-development, asset-specific partnerships, translational validation, biomarker integration and therapeutic optimization.

Discuss a partnership ↗